Log in

NASDAQ:ARWRArrowhead Pharmaceuticals News Headlines

$28.94
+2.82 (+10.80 %)
(As of 04/7/2020 02:59 AM ET)
Add
Compare
Today's Range
$26.75
Now: $28.94
$29.07
50-Day Range
$20.56
MA: $31.30
$41.27
52-Week Range
$17.30
Now: $28.94
$73.72
Volume1.26 million shs
Average Volume1.76 million shs
Market Capitalization$2.94 billion
P/E Ratio54.60
Dividend YieldN/A
Beta1.94

Headlines

Arrowhead Pharmaceuticals (NASDAQ ARWR) News Headlines

Source:
DateHeadline
Former gene-silencing rivals bury the hatchet with new partnershipFormer gene-silencing rivals bury the hatchet with new partnership
finance.yahoo.com - April 6 at 10:57 AM
 Analysts Anticipate Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Will Post Quarterly Sales of $21.90 Million Analysts Anticipate Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Will Post Quarterly Sales of $21.90 Million
www.americanbankingnews.com - April 2 at 4:28 AM
B. Riley Reaffirms "Buy" Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)B. Riley Reaffirms "Buy" Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)
www.americanbankingnews.com - April 1 at 7:02 PM
 Analysts Anticipate Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Will Announce Earnings of $0.02 Per Share Analysts Anticipate Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Will Announce Earnings of $0.02 Per Share
www.americanbankingnews.com - March 31 at 1:49 PM
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Short Interest Down 5.2% in MarchArrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Short Interest Down 5.2% in March
www.americanbankingnews.com - March 30 at 1:00 AM
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Given Consensus Rating of "Hold" by AnalystsArrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - March 26 at 5:58 AM
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to Market Perform by SVB LeerinkArrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded to Market Perform by SVB Leerink
www.americanbankingnews.com - March 24 at 9:46 AM
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Coverage Initiated by Analysts at Goldman Sachs GroupArrowhead Pharmaceuticals (NASDAQ:ARWR) Coverage Initiated by Analysts at Goldman Sachs Group
www.americanbankingnews.com - March 17 at 6:40 PM
Short Interest in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Decreases By 8.5%Short Interest in Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) Decreases By 8.5%
www.americanbankingnews.com - March 14 at 8:49 AM
B. Riley Trims Arrowhead Pharmaceuticals (NASDAQ:ARWR) Target Price to $57.00B. Riley Trims Arrowhead Pharmaceuticals (NASDAQ:ARWR) Target Price to $57.00
www.americanbankingnews.com - March 13 at 10:54 PM
Arrowhead up 3% on launch of new NASH studyArrowhead up 3% on launch of new NASH study
seekingalpha.com - March 3 at 2:40 PM
Arrowhead Pharmaceuticals to Participate in Upcoming March 2020 ConferencesArrowhead Pharmaceuticals to Participate in Upcoming March 2020 Conferences
finance.yahoo.com - March 2 at 5:55 PM
Arrowhead Pharmaceuticals: Why JNJ-3989 May Become A First-Line Therapy For Chronic HBVArrowhead Pharmaceuticals: Why JNJ-3989 May Become A First-Line Therapy For Chronic HBV
seekingalpha.com - February 25 at 2:06 PM
Heres Why Arrowhead Pharmaceuticals Fell 33.9% in JanuaryHere's Why Arrowhead Pharmaceuticals Fell 33.9% in January
www.fool.com - February 6 at 6:44 PM
Arrowhead FQ1 revenue matches viewsArrowhead FQ1 revenue matches views
seekingalpha.com - February 5 at 6:51 PM
Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
finance.yahoo.com - February 5 at 6:51 PM
Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter ResultsArrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results
finance.yahoo.com - February 5 at 6:51 PM
Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?
finance.yahoo.com - February 3 at 1:46 PM
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) A Volatile Stock?Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) A Volatile Stock?
finance.yahoo.com - January 24 at 5:54 AM
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter ResultsArrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results
finance.yahoo.com - January 22 at 7:50 AM
Leerink sees 43% downside in Arrowhead in premarket analyst actionLeerink sees 43% downside in Arrowhead in premarket analyst action
seekingalpha.com - January 21 at 7:46 AM
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Arrowhead Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of DirectorsSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Arrowhead Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - January 16 at 6:18 PM
Buy Arrowhead Pharmaceuticals Now At Near The Institutional DiscountBuy Arrowhead Pharmaceuticals Now At Near The Institutional Discount
seekingalpha.com - January 8 at 8:27 PM
Best Stocks 2019: Innovation, As Usual, Wins The Day — Or Even The YearBest Stocks 2019: Innovation, As Usual, Wins The Day — Or Even The Year
finance.yahoo.com - December 27 at 6:52 PM
Arrowhead launches mid-stage study of RNAi drug in rare liver disorderArrowhead launches mid-stage study of RNAi drug in rare liver disorder
seekingalpha.com - December 20 at 8:12 AM
Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver DiseaseArrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
finance.yahoo.com - December 20 at 8:12 AM
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
finance.yahoo.com - December 16 at 6:26 PM
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver DiseaseArrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease
finance.yahoo.com - December 16 at 8:24 AM
Credit Suisse cuts view on Gilead in premarket analyst actionCredit Suisse cuts view on Gilead in premarket analyst action
seekingalpha.com - December 13 at 8:42 AM
Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of DirectorsArrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors
finance.yahoo.com - December 13 at 8:42 AM
Did Hedge Funds Drop The Ball On Arrowhead Research Corp (ARWR) ?Did Hedge Funds Drop The Ball On Arrowhead Research Corp (ARWR) ?
finance.yahoo.com - December 11 at 6:21 PM
Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell CarcinomaArrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
finance.yahoo.com - December 11 at 8:19 AM
Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 MillionArrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million
finance.yahoo.com - December 6 at 5:27 PM
Arrowhead Pharmaceuticals Reaches Analyst Target PriceArrowhead Pharmaceuticals Reaches Analyst Target Price
www.nasdaq.com - December 4 at 12:23 PM
Arrowhead down 8% premarket on pricing equity offeringArrowhead down 8% premarket on pricing equity offering
seekingalpha.com - December 4 at 7:22 AM
19 Healthcare Stocks Moving In Tuesdays Pre-Market Session19 Healthcare Stocks Moving In Tuesday's Pre-Market Session
www.msn.com - December 3 at 7:53 PM
Heres Why Arrowhead Pharmaceuticals Is Soaring TodayHere's Why Arrowhead Pharmaceuticals Is Soaring Today
www.fool.com - December 3 at 2:52 PM
Arrowhead down 3% after hours on equity offeringArrowhead down 3% after hours on equity offering
seekingalpha.com - December 3 at 8:28 AM
This Highly Rated Biotech Company Just Tumbled 13% On A Public OfferingThis Highly Rated Biotech Company Just Tumbled 13% On A Public Offering
finance.yahoo.com - December 2 at 6:38 PM
This Biotech With 488% Growth In 2019 Just Gained A Price-Target BoostThis Biotech With 488% Growth In 2019 Just Gained A Price-Target Boost
finance.yahoo.com - November 29 at 3:21 PM
Biotech Arrowhead Stock’s Surge Will Continue, Analyst SaysBiotech Arrowhead Stock’s Surge Will Continue, Analyst Says
finance.yahoo.com - November 29 at 10:21 AM
Arrowhead Pharmaceuticals, Inc. Just Missed Earnings And Its EPS Looked Sad - But Analysts Have Updated Their ModelsArrowhead Pharmaceuticals, Inc. Just Missed Earnings And Its EPS Looked Sad - But Analysts Have Updated Their Models
finance.yahoo.com - November 27 at 8:53 AM
Edited Transcript of ARWR earnings conference call or presentation 25-Nov-19 9:30pm GMTEdited Transcript of ARWR earnings conference call or presentation 25-Nov-19 9:30pm GMT
finance.yahoo.com - November 26 at 8:23 AM
Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019
finance.yahoo.com - November 18 at 9:55 AM
Arrowhead Pharmaceuticals Announces Planned Management TransitionArrowhead Pharmaceuticals Announces Planned Management Transition
www.bloomberg.com - November 15 at 8:15 AM
Arrowhead Shares Are Still Alerting Big Buy SignalsArrowhead Shares Are Still Alerting Big Buy Signals
finance.yahoo.com - November 13 at 3:29 PM
Why It Could Soon Be Time To Take Profits In This Highflying Biotech StockWhy It Could Soon Be Time To Take Profits In This Highflying Biotech Stock
finance.yahoo.com - November 8 at 3:42 PM
Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019
finance.yahoo.com - November 8 at 8:41 AM
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis ConferenceArrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference
finance.yahoo.com - October 31 at 1:56 PM
The Arrowhead Pharmaceuticals (NASDAQ:ARWR) Share Price Is Up 557% And Shareholders Are DelightedThe Arrowhead Pharmaceuticals (NASDAQ:ARWR) Share Price Is Up 557% And Shareholders Are Delighted
finance.yahoo.com - October 26 at 12:35 PM
This page was last updated on 4/7/2020 by MarketBeat.com Staff

Featured Article: Insider Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel